Showing results (51-60 of 106) with videos related to

Sort By:
Pageof 11
Folia Biologica|January 1, 1997
CTLL assay: comparison of two methods for IL-2 determinationM Indrová, E Pajtasz-Piasecka, C Radzikowski, et al.
Glycoconjugate Journal|June 1, 1992
Application of chemically desialylated and degalactosylated human glycophorin for induction and characterization of anti-Tn monoclonal antibodiesM Duk, I Steuden, D Duś, et al.
Journal of Medicinal Chemistry|November 1, 1985
N-(Phosphonoacetyl)amino phosphonates. Phosphonate analogues of N-(phosphonoacetyl)-L-aspartic acid (PALA)P Kafarski, B Lejczak, P Mastalerz, et al.
Cancer Detection and Prevention. Supplement : Official Publication of the International Society for Preventive Oncology, Inc|January 1, 1987
Protein deficiency reduces natural antitumor immunityR Ruffmann, E Schlick, T Tartaris, et al.
Archivum Immunologiae Et Therapiae Experimentalis|January 1, 1986
Comparative studies on biological activity of /+/R and /-/S enantiomers of cyclophosphamide and ifosfamide. I. Antitumour effect of cyclophosphamide and ifosfamide enantiomersM Paprocka, H Kuśnierczyk, W Budzyński, et al.
Journal of Experimental & Clinical Cancer Research : CR|January 6, 2001
The role of GABA-ergic system in human mammary gland pathology and in growth of transplantable murine mammary cancerA Opolski, M Mazurkiewicz, J Wietrzyk, et al.
Archivum Immunologiae Et Therapiae Experimentalis|January 1, 1989
Potentiation of cyclophosphamide-induced enhancement of experimental metastasis by splenectomyL Strzadała, J Rak, E Zioło, et al.
Clinical & Experimental Metastasis|May 1, 1990
Lectin-resistant variants of mouse Lewis lung carcinoma cells. II. Altered glycosylation of membrane glycoproteinsH Debray, D Dus, P Hueso, et al.
Glycoconjugate Journal|January 1, 1989
Glycosphingolipids of human urothelial cell lines with different grades of transformationM Ugorski, P Påhlsson, D Dus, et al.
Archivum Immunologiae Et Therapiae Experimentalis|January 1, 1989
Transplantable mouse mammary adenocarcinoma 16/c as a model in experimental cancer therapy. III. Sensitivity to antitumor drugsJ Rak, H Kuśnierczyk, L Strzadała, et al.
Pageof 11